Ticker

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026.

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced that the Company will change the ratio of its American Depositary Shares (ADSs) to ordinary shares from one ADS representing two thousand (2,000) ordinary shares to a new ratio of one…

Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report) was the target of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 209,369 shares, a decrease of 16.1% from the February 12th total of 249,671 shares. Approximately 0.7% of the shares of the stock are sold short. Based

Highlights strategic progress achieved under Abizer Gaslightwala's leadership, including advancement of AKTX-101 and expansion of Akari's ADC pipeline

Akari Therapeutics PLC (NASDAQ: AKTX - Get Free Report)'s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.26 and traded as high as $0.2773. Akari Therapeutics shares last traded at $0.2570, with a volume of 760,478 shares traded. Analysts Set New